Switch to Donald Yapp's research page...

2008

1. Baker JHE, Lam J, Kyle AH, Sy J, Oliver T, Co S, Dragowska WH, Ramsay E, Anantha M, Ruth TJ, Adam MJ, Yung A, Kozlowski P, Minchinton AI, Ng SSW, Bally MB and Yapp DTT. Irinophore C^TM, A Novel Nano-Formulation of Irinotecan, Alters Tumor Vascular Function, and Enhances the Distribution of 5-FU and Doxorubicin Clin Cancer Res 2008 Nov 15:14(22):7260-7l. (2008).
    [View Abstract - PubMed 19010842]  Request Paper

2. Edwards LA, Woo J, Huxam LA, Verreault M, Chiu G, Rajput A, Kyle AH, Karle J, Dragowska WH, Yapp D, Yan H, Minchinton AK, Huntsman D, Daynard T, Waterhouse DN, Thiessen B, Dedhar S and Bally MB. Suppression of VEGF Secretion and Changes in Glioblastoma Mmultiforme Microenvironment by Inhibition of Integrin-Linked Kinase (ILK) Mol Cancer Ther 2008 Jan;7(1):59-70. (2008).
    [View Abstract - PubMed 18202010]  Request Paper

3. Ferreira CL, Yapp DT, Lamsa E, Gleave M, Bensimon C, Jurek P and Kiefer GE. Evaluation of novel bifunctional chelates for the development of Cu-64-based radiopharmaceuticals Nucl Med Biol. 2008 Nov;35(8):875-82 (2008).
    [View Abstract - PubMed 19026949]  Request Paper

4. Hoff MN, Yapp DT, Yung AC, Oliver TS, Kozlowski P. In vivo measurement of the hypoxia marker EF5 in Shionogi tumours using (19)F magnetic resonance spectroscopy Int J Radiat Biol. 2008 Mar;84(3):237-42 (2008).
    [View Abstract - PubMed 18300024]  Request Paper

2007

5. Dragowska WH, Verreault M, Yapp DT, Warburton C, Edwards L, Ramsay EC, Huxham LA, Minchinton AI, Gelmon K, Bally MB. Decreased levels of hypoxic cells in gefitinib treated ER(+) HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin. Breast Cancer Res Treat. . (2007).
    [View Abstract - PubMed 17347776]  Request Paper

6. Webb MS, Boman N, Masin D, Yapp D, Ramsay E, Chiu GNC, Cullis PR, and Bally MB . A Cationic Liposomal Vincristine Formulation with Improved Vincristine Retention, Extended Circulation Lifetime and Increased Anti-Tumor Activity Letters in Drug Design and Discovery September 2007;4(6):426-433. (2007).
    Request Paper

7. Yapp DT, Woo J, Kartono A, Sy J, Oliver T, Skov KA, Koch CJ, Adomat H, Dragowska WH, Fazli L, Ruth T, Adam MJ, Green D, Gleave M. Non-invasive evaluation of tumour hypoxia in the Shionogi tumour model for prostate cancer with 18F-EF5 and positron emission tomography. BJU Int. 99(5):1154-60. Epub 2007 Feb 19. (2007).
    [View Abstract - PubMed 17309552]  Request Paper

2006

8. Waterhouse DN, Gelmon KA, Klasa R, Chi K, Huntsman D, Ramsay E, Wasan E, Edwards L, Tucker C, Zastre J, Wang YZ, Yapp D, Dragowska W, Dunn S, Dedhar S, Bally MB. Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers. Curr Cancer Drug Targets. 6(6):455-89. (2006).
    [View Abstract - PubMed 17017873]  Request Paper

2004

9. Dragowska WH, Warburton C, Yapp DT, Minchinton AI, Hu Y, Waterhouse DN, Gelmon K, Skov K, Woo J, Masin D, Huxham LA, Kyle AH, Bally MB. HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization. Mol Cancer Res. 2(11):606-19. (2004).
    [View Abstract - PubMed 15561777]  Request Paper

10. Skov K, Adomat H, Bowden M, Dragowska W, Gleave M, Koch CJ, Woo J, Yapp DT. Hypoxia in the androgen-dependent Shionogi model for prostate cancer at three stages. Radiat Res. 162(5):547-53. (2004).
     [View Abstract - PubMed 15624309]  Request Paper

2003

11. Yapp DT, Yap SY. Lansium domesticum: skin and leaf extracts of this fruit tree interrupt the lifecycle of Plasmodium falciparum, and are active towards a chloroquine-resistant strain of the parasite (T9) in vitro. J Ethnopharmacol. 85(1):145-50. (2003).
     [View Abstract - PubMed 12576213]  Request Paper

2002

12. Yapp DT,Steed J, Yap SY and Houghton P.J.. The isolation and structural characterization of n-Methyl-4-hydroxyproline from the fruit skin of Lansium spp. Cryst. Acta E. Vol. E58, p. 988-989 (2002).
     Request Paper

1999

13. Doiron A, Yapp DT, Olivares M, Zhu JX, Lehnert S. Tumor radiosensitization by sustained intratumoral release of bromodeoxyuridine. Cancer Res. 59(15):3677-81. (1999).
     [View Abstract - PubMed 10446981]  Request Paper

14. Yapp DT, Lloyd DK, Zhu J, Lehnert S. Radiosensitization of a mouse tumor model by sustained intra-tumoral release of etanidazole and tirapazamine using a biodegradable polymer implant device. Radiother Oncol. 53(1):77-84. (1999).
     [View Abstract - PubMed 10624857]  Request Paper

1998

15. Clas SD, Yapp DT and Zhu XX. Polymeric materials for pharmaceutical applications: Processing and testing. Recent Res. Devel. in Macromol. Res.3, p. 475 - 503 (1998).
     Request Paper

16. Yapp DT, Lloyd DK, Zhu J, Lehnert SM. The potentiation of the effect of radiation treatment by intratumoral delivery of cisplatin. Int J Radiat Oncol Biol Phys. 42(2):413-20. (1998).
     [View Abstract - PubMed 9788424]  Request Paper

17. Yapp DT, Lloyd DK, Zhu J, Lehnert SM. Cisplatin delivery by biodegradable polymer implant is superior to systemic delivery by osmotic pump or i.p. injection in tumor-bearing mice. Anticancer Drugs. 9(9):791-6. (1998).
     [View Abstract - PubMed 9840725]  Request Paper

1997

18. Yapp DT, Lloyd DK, Zhu J, Lehnert SM. Tumor treatment by sustained intratumoral release of cisplatin: effects of drug alone and combined with radiation. Int J Radiat Oncol Biol Phys. 39(2):497-504. (1997).
     [View Abstract - PubMed 9308956]  Request Paper

19. Yapp DT, Rettig SJ, James BR and Skov KA. Bidentate sulfoxide complexes of ruthenium(II) and their preliminary biological assessment in vitro Inorg. Chem. Vol. 36, p. 5635 - 5641 (1997).
     Request Paper

1993

20. Jaswal J, Yapp DT, Rettig SJ, James BR and Skov KA. Routes to ruthenium(II)bromo(sulfoxide) complexes, including the synthesis and structural characterization of a neutral dilithium/diruthenium(II) complex containing terminal and bridging tetramethylenesulfoxide ligands Inorg. Chim. Acta. Vol. 207, p. 97 - 103 (1993).
     Request Paper

1992

21. Jaswal J, Yapp DT, Rettig SJ, James BR and Skov KA. A diruthenium(II)-dilithium complex containing four different bonding types of tetramethylenesulfoxide ligands J. Chem. Soc. Chem. Comm. p. 1528 - 1530 (1992).
     Request Paper

1990

22. Yapp DT, Jaswal J, Rettig SJ, James BR and Skov KA. he synthesis and structural characterization of cis-dichlorotetrakis (tetramethylenesulfoxide-S) ruthenium(II) and mertrichlorotris(tetrahydrothiophene) ruthenium(III). Inorg. Chim. Acta. 177, p. 199 - 204 (1990).
     Request Paper